JARDIANCE (empagliflozin tablets) Patient Assistance Program
Don’t let the high cost of brand SGLT2 inhibitor disrupt your diabetes, heart failure, or chronic kidney disease care. We help eligible patients access Jardiance (empagliflozin tablets) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Jardiance (empagliflozin) is FDA-approved to improve glycemic control in adults and children ≥10 years with type 2 diabetes, reduce the risk of cardiovascular death in adults with T2DM and established cardiovascular disease, reduce the risk of cardiovascular death and hospitalization for heart failure in adults with HF (HFrEF and HFpEF), and reduce the risk of sustained decline in eGFR, end-stage kidney disease, CV death, and HF hospitalization in adults with CKD at risk of progression. SGLT2 inhibitor — among the most comprehensively studied agents in the class with strongest CV mortality data (EMPA-REG OUTCOME, EMPEROR-Reduced, EMPEROR-Preserved, EMPA-KIDNEY).
- Without assistance, brand Jardiance costs commonly run approximately $570–$730 per 30-day supply.
- Through AffordMyPrescriptions, qualifying patients can access Jardiance for a flat $69.95 per month.
- Jardiance is included in the first wave of Medicare Part D drug price negotiation under the Inflation Reduction Act — negotiated price effective 2026 will substantially reduce cost for Medicare beneficiaries. Other SGLT2 inhibitors: dapagliflozin (Farxiga — also IRA negotiated), canagliflozin (Invokana), ertugliflozin (Steglatro), bexagliflozin (Brenzavvy — typically cheaper class option). Generic metformin remains first-line for T2DM. Other diabetes lines (mostly generic): sulfonylureas, pioglitazone, DPP-4 inhibitors, GLP-1 receptor agonists (Ozempic, Trulicity, Mounjaro/Zepbound, Victoza/Saxenda generic emerging), basal insulins. HF/CKD foundational GDMT: ARNI (Entresto generic emerging), ACE inhibitors/ARBs (generic), beta-blockers (generic), MRAs (generic spironolactone, eplerenone; Kerendia/finerenone for T2DM CKD).
What Is Jardiance Prescription Assistance Program?
The Jardiance Patient Assistance Program is a manufacturer-sponsored initiative that helps eligible patients access Jardiance (used for type 2 diabetes glycemic control, cardiovascular risk reduction, heart failure management, and chronic kidney disease) at little or no cost when they meet specific income, insurance, and clinical criteria. The program is free to apply for, but the enrollment process involves detailed applications, endocrinology, cardiology, or nephrology coordination, supporting documentation, and ongoing renewal — which can be overwhelming when you are managing diabetes, heart failure, or kidney disease.
At AffordMyPrescriptions, our Patient Advocates handle the entire Jardiance PAP enrollment for a flat $69.95 per month. We complete the application, coordinate with your prescriber for required medical documentation, follow up with the manufacturer’s program until approval, manage your refills, and handle annual re-certification — so you never face a gap in your Jardiance SGLT2 inhibitor therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Jardiance enrollment — from the initial application through ongoing refills and annual re-enrollment — so you never face a gap in your diabetes and cardiorenal treatment.
Pharmacy Price Comparison
- Without assistance, Jardiance costs hundreds of dollars per month at retail pharmacies. Discount cards and pharmacy coupons offer some relief, but they don't come close to what a Patient Assistance Program provides if you qualify. The table below compares typical retail pricing across major pharmacies to what you'd pay with our Jardiance advocacy service:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$710/mo | Save ~$640/mo |
| CVS Pharmacy | ~$730/mo | Save ~$660/mo |
| Walmart | ~$600/mo | Save ~$530/mo |
| Costco | ~$570/mo | Save ~$500/mo |
| Medicare negotiated (2026) | ~$295/mo | Save under IRA negotiation |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Jardiance — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Jardiance Prescription Program?
The Jardiance Patient Assistance Program is free to apply and provides medication at no cost if approved. But the process involves detailed applications, prescriber coordination, documentation, and ongoing management — applications that are commonly delayed or denied when paperwork is incomplete. Our $69.95 per month covers full advocacy: applications, doctor coordination, documentation, refill management, and re-enrollment — so you focus on your health, not paperwork. Jardiance has the strongest cardiovascular mortality data in the SGLT2 class, but Brenzavvy and Mark Cuban Cost Plus offer substantially cheaper class options.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Jardiance:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $570–$730 per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly from the manufacturer
- We manage all paperwork, refills, and renewals
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Jardiance assistance.
- You are a U.S. citizen or legal resident
- You Have A Valid Jardiance Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Jardiance:
Jardiance is a sodium-glucose cotransporter 2 (SGLT2) inhibitor with the most extensive outcomes data in the class — demonstrating cardiovascular mortality reduction in T2DM with ASCVD (EMPA-REG OUTCOME), heart failure benefits across the ejection fraction spectrum (EMPEROR-Reduced and EMPEROR-Preserved), and CKD progression reduction (EMPA-KIDNEY). Mechanism is SGLT2 blockade in the proximal renal tubule producing glucosuria, modest weight loss, blood pressure reduction, and natriuresis.
How Jardiance Works:
Type 2 diabetes drives cardiovascular and kidney complications through hyperglycemia, hypertension, dyslipidemia, and inflammation. Heart failure and chronic kidney disease share inflammatory and hemodynamic mechanisms with cardiometabolic disease — and SGLT2 inhibitors provide benefits in HF and CKD independent of diabetes.
Empagliflozin selectively inhibits SGLT2 in the proximal renal tubule — reduces glucose reabsorption — produces glucosuria, modest weight loss, mild blood pressure reduction, and natriuresis. SGLT2 class benefits in HF and CKD extend beyond glucose lowering — reduced glomerular hyperfiltration, improved cardiac energetics, reduced cardiac fibrosis, and natriuretic effects. The EMPA-REG OUTCOME, EMPEROR, and EMPA-KIDNEY trials established broad cardiorenal benefits across the spectrum.
Empagliflozin selectively inhibits SGLT2 in the proximal renal tubule — reduces glucose reabsorption — produces glucosuria, modest weight loss, mild blood pressure reduction, and natriuresis. SGLT2 class benefits in HF and CKD extend beyond glucose lowering — reduced glomerular hyperfiltration, improved cardiac energetics, reduced cardiac fibrosis, and natriuretic effects. The EMPA-REG OUTCOME, EMPEROR, and EMPA-KIDNEY trials established broad cardiorenal benefits across the spectrum.
Form and use:
Jardiance 10 mg or 25 mg tablets once daily in the morning, with or without food. Starting dose 10 mg for HF/CKD or T2DM; may increase to 25 mg for additional glucose lowering. Recent guidance supports use down to eGFR 20 for cardiorenal protection. Hold during acute illness (especially with poor oral intake) to reduce DKA risk. Hold 3–4 days before planned surgery. Pediatric T2DM (≥10 years): 10 mg once daily.
Generic availability:
No US generic Jardiance yet. Other SGLT2 inhibitors: dapagliflozin (Farxiga — strong HF and CKD data), canagliflozin (Invokana — HF and renal outcomes with FDA labeling note on amputation risk from CANVAS), ertugliflozin (Steglatro — weaker outcomes evidence), bexagliflozin (Brenzavvy — typically lower-priced). Cheaper SGLT2 access: Mark Cuban Cost Plus carries some at discounted prices. Other T2DM lines: metformin (generic, foundational first-line), generic sulfonylureas (caution hypoglycemia), generic pioglitazone, DPP-4 inhibitors (Januvia going generic, Tradjenta), GLP-1 receptor agonists (Ozempic/Rybelsus/Wegovy, Trulicity, Mounjaro/Zepbound, Victoza/Saxenda generic emerging), basal insulins (glargine biosimilars, Toujeo, degludec/Tresiba). For HF: ARNI (Entresto — generic emerging), ACE/ARB (generic), beta-blockers (carvedilol, metoprolol succinate, bisoprolol — generic), MRAs (spironolactone, eplerenone — generic), finerenone (Kerendia) for T2DM CKD, ivabradine (Corlanor) for select HF patients, vericiguat (Verquvo) for advanced HF. For CKD: ACE/ARB foundational, finerenone, potassium binders (patiromer, sodium zirconium cyclosilicate/Lokelma) for hyperkalemia.
Warnings:
**Class concerns: euglycemic diabetic ketoacidosis (especially during illness, surgery, fasting, alcohol — hold sick days, stop 3–4 days pre-surgery), genital mycotic infections (yeast — counsel hygiene), urinary tract infections, Fournier’s gangrene (rare necrotizing fasciitis), volume depletion and hypotension (caution with diuretics, elderly), AKI (especially with volume depletion), hyperkalemia (with K-sparing medications), bone fracture risk (canagliflozin specifically; less concerning with empagliflozin), urosepsis.** Not for T1DM (DKA risk too high). Initial small eGFR drop expected (hemodynamic) — reversible. Long-term renoprotective and cardioprotective. Discuss DKA recognition and sick-day rules.
FAQ (Frequently Asked Questions)
How much does Jardiance cost without insurance?
Brand Jardiance $570–$730 per month. Under the IRA Medicare drug price negotiation effective 2026, the negotiated maximum fair price is approximately $295 per month for Medicare beneficiaries. Brenzavvy (alternative SGLT2 inhibitor with class effects) costs about $50 per month — substantially cheaper class option.
Why is an SGLT2 inhibitor like Jardiance added when generic metformin is much cheaper?
Metformin remains foundational first-line for T2DM and very cheap. SGLT2 inhibitors are added because the class — and Jardiance specifically — has strong outcomes data: reduced cardiovascular death, reduced heart failure hospitalization, slowed CKD progression. Per ADA/EASD guidelines, SGLT2 inhibitors are preferred 2nd-line in patients with HF, CKD, or established ASCVD.
What is the difference between Jardiance and Farxiga?
Both are SGLT2 inhibitors with major cardiorenal benefits. Jardiance has the strongest CV mortality data in the class (EMPA-REG OUTCOME first showed mortality benefit). Farxiga has strong CKD data (DAPA-CKD) and HFpEF data (DELIVER) at slightly lower starting dose. Trials show overlap in benefits. Choice often by insurance coverage, specific outcomes evidence the prescriber wants to emphasize, and cost. Brenzavvy is a cheaper class option.
What is the difference between Jardiance and Invokana?
Both SGLT2 inhibitors. Jardiance has stronger CV mortality data and lacks the amputation labeling note carried by Invokana (canagliflozin from CANVAS trial). Real-world differences may be modest, and class benefits overlap considerably.
What is diabetic ketoacidosis (DKA) risk with Jardiance?
Euglycemic DKA possible during illness, surgery, fasting, very low-carb diet, alcohol use, or in T1DM (contraindicated). Hold sick days; stop 3–4 days before planned surgery. Recognize nausea, vomiting, abdominal pain, malaise, rapid breathing as warning signs and check ketones.
Should I take Jardiance if I have heart failure even without diabetes?
Yes — Jardiance is FDA-approved for HF regardless of diabetes status, including both reduced ejection fraction (EMPEROR-Reduced) and preserved ejection fraction (EMPEROR-Preserved). Reduces CV death and HF hospitalization in addition to standard GDMT (ARNI, beta-blocker, MRA, diuretic as needed).
How does Jardiance affect my kidneys?
Initial small eGFR drop expected and reversible — reflects normalization of glomerular hyperfiltration. Long-term Jardiance is renoprotective — slows CKD progression and reduces kidney failure (EMPA-KIDNEY trial). Recent guidance supports use down to eGFR 20 for cardiorenal protection.
What happens if my Jardiance Patient Assistance Program application is denied?
We help explore Brenzavvy (much cheaper SGLT2 alternative), Mark Cuban Cost Plus, generic metformin foundation therapy, Farxiga copay programs (alternative SGLT2 with strong evidence), GLP-1 receptor agonist programs for diabetes and CV benefits, ARNI generic for HF, ACE/ARB/beta-blocker/MRA foundational HF therapies, finerenone (Kerendia) for T2DM CKD, ADA/AADE resources, foundation aid (American Heart Association, National Kidney Foundation, Patient Access Network), and IRA negotiated Medicare pricing (effective 2026).
Take Control of Your Medication Costs
Diabetes, heart failure, and chronic kidney disease management should not be skipped over cost. Jardiance has the strongest cardiovascular mortality evidence in the SGLT2 class — and substantially cheaper alternatives are available. Our Jardiance advocacy team is ready to verify your eligibility, complete the manufacturer application on your behalf, and manage your prescription through approval, delivery, and renewal — for a flat $69.95 per month. If we cannot help you access Jardiance through a Patient Assistance Program, you are not charged. Call (833) 556-2729 or check your eligibility online today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.